ESTA vs JNJ: How Establishment Labs Holdings Inc. and Johnson & Johnson Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JNJ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ESTA and JNJ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ESTA and JNJ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Establishment Labs designs and manufactures silicone breast implants and related devices under the Motiva brand, made at two company-owned plants in Costa Rica and sold in roughly 85 countries. The core product is a family of implants built around SmoothSilk, a proprietary nanotextured shell surface intended to reduce friction and bacterial attachment and, by extension, the rate of capsular contracture. Around that implant the company has built a set of procedures rather than just a product line: Mia Femtech, a minimally invasive breast harmonization procedure done under local anesthesia with no visible breast scar, and Preservé, a tissue-preserving minimally invasive approach for primary augmentation and mastopexy augmentation that works across a wider range of cases and larger sizes. Motiva Flora, a tissue expander with an integrated radio-frequency port for post-mastectomy reconstruction, extends the same platform into the reconstructive market. More than five million Motiva devices have been placed globally since launch.

Full ESTA guide

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ESTA drivers: United States share gain against a two-brand incumbency; The minimally invasive platform as a margin and category lever.
• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The balance sheet is the first thing to weigh: roughly $264 million of debt against about $71 million of cash, secured by a first-priority lien on substantially all assets, at a company that has not yet generated positive free cash flow. For JNJ, j&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ESTA if you believe its drivers more; JNJ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ESTA and JNJ guides.

ESTA. There is no meaningful earnings multiple here because there are no earnings, so the stock is valued on sales and on the credibility of the US ramp. At roughly 9 times trailing revenue, ESTA prices at a premium to most profitable medtech peers, which is the market's way of paying forward for a company growing above 30% with gross margins above 70%. Full-year 2026 guidance of $269 million to $271 million implies roughly 28% growth, and the sell side has clustered targets between about $76 and $117, a wide band that reflects genuine disagreement about how fast a duopoly cracks.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

Headline figures (approximate, August 2026): ESTA shows revenue (ttm) ~$246 million, up ~39% year over year, q2 2026 revenue ~$67.5 million, up ~31.7%, with Motiva USA at ~$24.7 million, gross margin / adjusted ebitda ~70.6% gross margin, adjusted EBITDA ~$3.7 million (third straight positive quarter), gaap net loss ~$11.7 million in Q2 2026 (~$0.39 a share), ~$38.9 million over the trailing twelve months; JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x.

ESTA and JNJ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ESTA and JNJ exposure against your real portfolio. It is not an investment adviser.